MA26747A1 - Composes inhibiteurs de recepteurs de nmda, leurs utilisations dans le traitement de troubles neuronaux et leurs preparations - Google Patents
Composes inhibiteurs de recepteurs de nmda, leurs utilisations dans le traitement de troubles neuronaux et leurs preparationsInfo
- Publication number
- MA26747A1 MA26747A1 MA26026A MA26026A MA26747A1 MA 26747 A1 MA26747 A1 MA 26747A1 MA 26026 A MA26026 A MA 26026A MA 26026 A MA26026 A MA 26026A MA 26747 A1 MA26747 A1 MA 26747A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- preparations
- nmda receptor
- inhibitor compounds
- receptor inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99114313 | 1999-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA26747A1 true MA26747A1 (fr) | 2004-12-20 |
Family
ID=8238635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA26026A MA26747A1 (fr) | 1999-07-21 | 2000-07-19 | Composes inhibiteurs de recepteurs de nmda, leurs utilisations dans le traitement de troubles neuronaux et leurs preparations |
Country Status (29)
Country | Link |
---|---|
US (1) | US6265426B1 (es) |
EP (1) | EP1070708B1 (es) |
JP (1) | JP3628946B2 (es) |
KR (1) | KR100383776B1 (es) |
CN (1) | CN1148357C (es) |
AR (1) | AR024790A1 (es) |
AT (1) | ATE257827T1 (es) |
AU (1) | AU773463B2 (es) |
BR (1) | BR0003075A (es) |
CA (1) | CA2314009C (es) |
CO (1) | CO5190713A1 (es) |
DE (1) | DE60007697T2 (es) |
DK (1) | DK1070708T3 (es) |
ES (1) | ES2211420T3 (es) |
HR (1) | HRP20000482A2 (es) |
HU (1) | HUP0002792A3 (es) |
ID (1) | ID26599A (es) |
IL (1) | IL137328A0 (es) |
MA (1) | MA26747A1 (es) |
MX (1) | MXPA00007069A (es) |
NO (1) | NO20003723L (es) |
NZ (1) | NZ505766A (es) |
PE (1) | PE20010349A1 (es) |
PL (1) | PL341616A1 (es) |
PT (1) | PT1070708E (es) |
SG (1) | SG98422A1 (es) |
TR (1) | TR200002097A3 (es) |
UY (1) | UY26253A1 (es) |
ZA (1) | ZA200003680B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
US7375136B2 (en) | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
CA2488117A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
US20060004088A1 (en) * | 2002-10-22 | 2006-01-05 | Oct Inc. | Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same |
US7084145B2 (en) * | 2002-10-25 | 2006-08-01 | Pfizer Inc. | Triazole compounds useful in therapy |
CN1747936A (zh) * | 2003-02-12 | 2006-03-15 | 特兰斯泰克制药公司 | 作为治疗试剂的取代吡咯衍生物 |
GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
DE602004027301D1 (de) * | 2003-12-22 | 2010-07-01 | Merck Sharp & Dohme | Alpha-hydroxyamide als bradykininantagonisten oder inverse agonisten |
NZ548208A (en) * | 2004-02-12 | 2010-09-30 | Transtech Pharma Inc | Substituted azole derivatives, compositions, and methods of use |
CN101374835B (zh) * | 2006-01-30 | 2012-04-25 | 转化技术制药公司 | 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法 |
JO3019B1 (ar) * | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
EP2118077B1 (en) | 2007-02-08 | 2014-12-24 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
EP2529623A3 (en) * | 2007-04-03 | 2013-03-13 | E. I. du Pont de Nemours and Company | Substituted benzene fungicides |
US20110158907A1 (en) * | 2007-04-19 | 2011-06-30 | The Trustees Of The Univeristy Of Pennsylvania | Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques |
US8420680B2 (en) * | 2007-06-29 | 2013-04-16 | Emory University | NMDA receptor antagonists for neuroprotection |
JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
RU2474579C2 (ru) | 2007-10-18 | 2013-02-10 | Янссен Фармацевтика Нв | Тризамещенные 1,2,4-триазолы |
AU2009226988B2 (en) | 2008-03-19 | 2013-05-23 | Janssen Pharmaceutica Nv | Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators |
WO2009118187A1 (en) * | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
JP5486591B2 (ja) | 2008-05-09 | 2014-05-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アセチルコリン受容体モジュレーターとしての三置換ピラゾール |
RU2532394C1 (ru) * | 2013-10-29 | 2014-11-10 | Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") | ПРИМЕНЕНИЕ БРОМИДА 1-β-ФЕНИЛЭТИЛ)-4-АМИНО-1,2,4-ТРИАЗОЛИЯ (ГИПЕРТРИЛ) КАК АКТИВНОЙ ОСНОВЫ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ КОРРЕКЦИИ НАРУШЕНИЙ ФУНКЦИОНИРОВАНИЯ НИТРОКСИДЕРГИЧЕСКОЙ СИСТЕМЫ ОРГАНОВ-МИШЕНЕЙ ПРИ ГОМОЦИСТЕИНЕМИИ И ОСТРЫХ НАРУШЕНИЯХ МОЗГОВОГО КРОВООБРАЩЕНИЯ |
BR112017003918B1 (pt) | 2014-08-29 | 2022-05-03 | Fmc Corporation | Composto, composições e mistura herbicida e método para o controle do crescimento da vegetação |
KR102512548B1 (ko) | 2017-12-22 | 2023-03-22 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물 |
US11912670B1 (en) | 2023-10-25 | 2024-02-27 | King Faisal University | Ethyl 4-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)butanoate as an antimicrobial compound |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1579352A (en) * | 1977-05-06 | 1980-11-19 | Lepetit Spa | 3,5-disubstituted-1h-1,2,4-triazoles |
DE19643037A1 (de) * | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
AU744297B2 (en) * | 1997-07-03 | 2002-02-21 | Neurogen Corporation | Certain diarylimidazole derivatives; a new class of NPY specific ligands |
DE19816880A1 (de) * | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
US7487474B2 (en) | 2003-01-02 | 2009-02-03 | Pdf Solutions, Inc. | Designing an integrated circuit to improve yield using a variant design element |
-
2000
- 2000-07-13 DE DE60007697T patent/DE60007697T2/de not_active Expired - Fee Related
- 2000-07-13 EP EP00114183A patent/EP1070708B1/en not_active Expired - Lifetime
- 2000-07-13 DK DK00114183T patent/DK1070708T3/da active
- 2000-07-13 ES ES00114183T patent/ES2211420T3/es not_active Expired - Lifetime
- 2000-07-13 AT AT00114183T patent/ATE257827T1/de not_active IP Right Cessation
- 2000-07-13 PT PT00114183T patent/PT1070708E/pt unknown
- 2000-07-17 CA CA002314009A patent/CA2314009C/en not_active Expired - Fee Related
- 2000-07-17 NZ NZ505766A patent/NZ505766A/en unknown
- 2000-07-17 PE PE2000000707A patent/PE20010349A1/es not_active Application Discontinuation
- 2000-07-17 AU AU48651/00A patent/AU773463B2/en not_active Ceased
- 2000-07-17 IL IL13732800A patent/IL137328A0/xx unknown
- 2000-07-18 SG SG200003981A patent/SG98422A1/en unknown
- 2000-07-19 ID IDP20000607D patent/ID26599A/id unknown
- 2000-07-19 MX MXPA00007069A patent/MXPA00007069A/es unknown
- 2000-07-19 MA MA26026A patent/MA26747A1/fr unknown
- 2000-07-19 TR TR2000/02097A patent/TR200002097A3/tr unknown
- 2000-07-19 AR ARP000103702A patent/AR024790A1/es active IP Right Grant
- 2000-07-19 US US09/619,518 patent/US6265426B1/en not_active Expired - Fee Related
- 2000-07-19 CO CO00054541A patent/CO5190713A1/es not_active Application Discontinuation
- 2000-07-20 KR KR10-2000-0041592A patent/KR100383776B1/ko not_active IP Right Cessation
- 2000-07-20 ZA ZA200003680A patent/ZA200003680B/xx unknown
- 2000-07-20 HR HR20000482A patent/HRP20000482A2/hr not_active Application Discontinuation
- 2000-07-20 UY UY26253A patent/UY26253A1/es not_active Application Discontinuation
- 2000-07-20 NO NO20003723A patent/NO20003723L/no unknown
- 2000-07-20 CN CNB001201816A patent/CN1148357C/zh not_active Expired - Fee Related
- 2000-07-20 HU HU0002792A patent/HUP0002792A3/hu unknown
- 2000-07-21 JP JP2000220748A patent/JP3628946B2/ja not_active Expired - Fee Related
- 2000-07-21 BR BR0003075-9A patent/BR0003075A/pt not_active Application Discontinuation
- 2000-07-21 PL PL00341616A patent/PL341616A1/xx not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA26747A1 (fr) | Composes inhibiteurs de recepteurs de nmda, leurs utilisations dans le traitement de troubles neuronaux et leurs preparations | |
TNSN98216A1 (fr) | Derives d'acide hydrauxamique, compositions pharmaceutiques les contenant et procede pour leur preparation | |
MA27647A1 (fr) | Antagonistes de ccr5 utiles comme agents therapeutiques | |
TNSN97193A1 (fr) | Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TR200000129T2 (tr) | Yepyeni spiroazabisiklik heterosiklik bileşikler. | |
MA29685B1 (fr) | Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques | |
TNSN98155A1 (fr) | Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation | |
ES2233931T3 (es) | Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos. | |
TNSN99126A1 (fr) | Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA25809A1 (fr) | Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase | |
MA27509A1 (fr) | Formulations a liberation prolongee contenant de la lamotrigine | |
TNSN98154A1 (fr) | Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant | |
MA24694A1 (fr) | Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant. | |
MX9603520A (es) | Derivados del acido hidroxamico y acido carboxilico, procesos para su preparacion y su uso. | |
MA30412B1 (fr) | Composés Pharmaceutiques | |
BR9609413A (pt) | Formulações de dieta e farmacêuticas para a profilaxia e o tratamento de distúrbios gastrintestinais | |
TNSN99006A1 (fr) | 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN00121A1 (fr) | Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26723A1 (fr) | Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98083A1 (fr) | Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
DK0763031T3 (da) | Piperazinderivater | |
NO20000093D0 (no) | (+)-Norcisaprid nyttig for 5-HT3 og 5-HT4-medierte forstyrrelser | |
MA26732A1 (fr) | Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation | |
CA2203310A1 (fr) | Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale | |
TNSN99002A1 (fr) | Composes nouveaux inhibiteurs de mmp, procede pour leur preparation et compositions pharmaceutiques les contenant |